Compare Essex Property Trust, Inc. (ESS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Sana Biotechnology Inc — how do they compare? Essex Property Trust, Inc. trades at $281.77 (market cap $18.15B), while Sana Biotechnology Inc trades at $3.76 (market cap $1.13B). The key difference: Essex Property Trust, Inc. is far larger — about 16.1× Sana Biotechnology Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ESS | SANA | |
|---|---|---|
Market Cap | $18.15B | $1.13B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $5.92 |
52-Week Low | $239.61 | $2.68 |
Enterprise Value | $24.75B | $1.05B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.92, down 0.46% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year guidance, reflecting strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is projected to moderate in 2026. Recent news highlights institutional buying by Amundi and recognition as a top GreenTech company.
The outlook is mixed: raised guidance and solid fundamentals support upside toward the $305.86 consensus price target, but technical weakness and a high debt load pose near-term risks. Investor sentiment is cautiously optimistic, with 40% of analysts rating the stock a Buy, though the bearish technical picture suggests potential volatility ahead.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
